Granix
Total Payments
$112,854
Transactions
32
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $112,854 | 32 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $112,854 | 32 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 ?g/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors | Teva Pharmaceuticals USA, Inc. | $112,854 | 1 |
Top Doctors Receiving Payments for Granix
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Indianapolis, IN | $112,212 | 31 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $641.28 | 1 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $112,854
Product Information
- Type Drug
- Total Payments $112,854
- Total Doctors 1
- Transactions 32
About Granix
Granix is a drug associated with $112,854 in payments to 1 healthcare providers, recorded across 32 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2018 to 2018. In 2018, $112,854 was paid across 32 transactions to 1 doctors.
The most common payment nature for Granix is "Unspecified" ($112,854, 100.0% of total).
Granix is associated with 1 research study, including "A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 ?g/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors" ($112,854).